Vatelizumab
Vatelizumab (GBR500) is a monoclonal antibody targeting the α2 subunit (CD49b) of very late antigen-2 (VLA-2) . Vatelizumab can be used for the research of multiple sclerosis[1].
Product Specifications
CAS Number
[1238217-55-4]
Product Name Alternative
GBR500
UNSPSC
12352203
Target
Others
Type
Inhibitory Antibodies
Related Pathways
Others
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/vatelizumab.html
Purity
99.90
Solubility
10 mM in DMSO
Smiles
[Vatelizumab]
Molecular Weight
(144.28 kDa)
References & Citations
[1]Johanna Breuer, et al. VLA-2 blockade in vivo by vatelizumab induces CD4+FoxP3+ regulatory T cells. Int Immunol. 2019 May 21;31 (6) :407-412.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6204541-01 0.1 mL
TTF-1 (BCH, Benign chorea, BHC, Homeobox protein Nkx2.1, NK2 homeobox 1, NKX2.1, NKX2A, TEBP, Thyroid nuclear factor-1, Thyroid specific enhancer binding protein, Thyroid transcription factor-1 (TTF-1), Tin man, TITF1, TTF-1) (BSA & Azide Free) (MaxLight
Ask
View Details